Press Releases

View past Indivior press releases below. Press releases are sorted by date, with the most current at the top of the list.

12.12.2018 | PDF Version

Court of Appeals for the Federal Circuit Declines to Immediately Issue Mandate After Preliminary Injunction Ruling

11.30.2018 | PDF Version

Indivior Prepays Debt

11.27.2018 | PDF Version

Indivior Conference Call, Previously-scheduled Capital Markets Day to be held in February 2019

11.23.2018 | PDF Version

Indivior Announces Health Canada Approval of SUBLOCADE™ (Buprenorphine Extended-Release) Injection for Patients with Moderate to Severe Opioid Use Disorder

11.21.2018 | PDF Version

Court of Appeals for the Federal Circuit Lifts Preliminary Injunction on Generic (buprenorphine and naloxone) Sublingual Film

11.20.2018 | PDF Version

Indivior Statement on Court Decision

11.19.2018 | PDF Version

PERSERIS™, the First Once-Monthly Risperidone-Containing Subcutaneous Long-Acting Injectable, Now Available in the U.S. for the Treatment of Schizophrenia in Adults

11.06.2018 | PDF Version

Indivior Announces Upcoming Investor Events

11.01.2018 | PDF Version

Indivior Q3 2018 Financial Results

10.24.2018 | PDF Version

SUPPORT for Patients and Communities Act of 2018

10.19.2018 | PDF Version

Third Quarter Results Notification & Call Information

09.26.2018 | PDF Version

Indivior Provides Update on Key Business Drivers and Expectations

09.12.2018 | PDF Version

Indivior unable to attend Investor Conference

09.10.2018 | PDF Version

Indivior Prepays $150 Million of Outstanding Debt

09.04.2018 | PDF Version

Morgan Stanley Annual Global Healthcare Conference

08.21.2018 | PDF Version

Holding(s) in Company 08/21/2018

08.10.2018 | PDF Version

Holding(s) in Company 8/10/2018

08.06.2018 | PDF Version

Holding(s) in Company 8/6/2018

07.31.2018 | PDF Version

Indivior Preliminary Injunction on Generic (buprenorphine and naloxone) Sublingual Film Upheld

07.30.2018 | PDF Version

Motion to Expedite DRL’s Appeal of Indivior’s Preliminary Injunction Granted-in-Part

07.27.2018 | PDF Version

FDA Approves PERSERIS™ (risperidone) for Extended-Release Injectable Suspension for the Treatment of Schizophrenia in Adults

07.25.2018 | PDF Version

Indivior H1 2018 Financial Results

07.13.2018

Indivior Is Granted Preliminary Injunction on Generic (buprenorphine and naloxone) Sublingual Film

07.11.2018 | PDF Version

Indivior Sees FY 2018 Net Revenue and Adjusted Net Income Below Previous Expectations

07.10.2018 | PDF Version

Indivior to Announce and Present Half Year 2018 Results on July 25th

06.28.2018

Indivior’s Temporary Restraining Order is Extended

06.15.2018 | PDF Version

Indivior Is Granted Temporary Restraining Order

06.15.2018 | PDF Version

Indivior Responds to Generic SUBOXONE® Approvals and Dr. Reddy’s Launch “At-Risk”

05.31.2018 | PDF Version

Indivior Receives Subpoena from California Department of Insurance

05.25.2018 | PDF Version

Indivior Announces Regulatory Submission to Australia’s Therapeutic Goods Administration (TGA) for SUBLOCADE™ (Buprenorphine Extended-Release) Injection for the Treatment of Opioid Dependence

05.17.2018 | PDF Version

Result of AGM

05.14.2018 | PDF Version

Indivior Enters into Settlement with Par Pharmaceutical in Patent Infringement Case

05.01.2018 | PDF Version

Indivior Q1 2018 Results On Track. FY 2018 Guidance Reconfirmed. Encouraging SUBLOCADE™ Launch.

04.20.2018 | PDF Version

Indivior Announces New Drug Submission to Health Canada for SUBLOCADE™ (Buprenorphine Extended-Release) Injection for the Treatment of Moderate to Severe Opioid Use Disorder

04.13.2018 | PDF Version

Patient-Reported Outcomes Data on SUBLOCADEᵀᴹ (Buprenorphine Extended-Release) Injection to be Presented as Late-Breaker at American Society of Addiction Medicine (ASAM) 49ᵗʰ Annual Conference

04.11.2018 | PDF Version

Indivior to Announce First Quarter 2018 Results on May 2nd and Host Conference Call

04.05.2018 | PDF Version

Indivior Files Complaints Asserting New SUBOXONE® Film Patent Against ANDA-filers

03.29.2018 | PDF Version

Indivior Enters Into an Exclusive Global License Agreement for C4X Discovery’s Orexin-1 (OX1) Antagonist Program

03.23.2018 | PDF Version

Indivior Responds To Court Ruling In ANDA Litigation And Announces Intention To Appeal

03.22.2018 | PDF Version

Annual Report & Accounts 2017 and Annual General Meeting 2018

03.01.2018 | PDF Version

SUBLOCADE™ (Buprenorphine Extended-Release) is Now Available as First and Only Monthly Injectable Buprenorphine in the U.S. to Treat Patients with Moderate to Severe Opioid Use Disorder

02.28.2018 | PDF Version

Indivior Chief Medical Officer Ponni Subbiah, M.D., Provides Testimony Before the US House of Representatives’ Energy and Commerce Subcommittee on Health Hearing on Combating the Opioid Crisis: Helping Communities Balance Enforcement and Patient Safety

02.15.2018 | PDF Version

Indivior PLC Full Year 2017 Financial Results

02.12.2018 | PDF Version

Indivior Files Complaints Asserting New SUBOXONE® Film Patent Against ANDA-filers

02.06.2018

Indivior to Announce Full Year 2017 Results on February 15th

02.01.2018 | PDF Version

Indivior Provides Update on Tax Position

01.11.2018 | PDF Version

JP Morgan Healthcare Conference Presentation – Strengthening Our Global Leadership in Treatment of Addiction

01.03.2018 | PDF Version